drugset / Trial / NCT07187960
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
Phase 3
Not yet recruiting
228 enrolled
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment
Summary
Evaluation of the efficacy and safety of TQB2825 injection compared to immunotherapy in the treatment of recurrent/refractory follicular lymphoma.
Timeline
- Start
- 2025-11
- Primary completion
- 2028-10
- Completion
- 2029-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rituximab | Monoclonal antibody | — | — |
| Subject | TQB2825 | Unknown | — | Intravenous |
| Comparator | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | — | — |
| Comparator | Carboplatin | Small molecule | — | — |
| Comparator | Cisplatin | Other / unclassified | — | — |
| Comparator | Cyclophosphamide | Other / unclassified | — | — |
| Comparator | Dexamethasone | Small molecule | — | — |
| Comparator | Doxorubicin | Other / unclassified | — | — |
| Comparator | Etoposide | Small molecule | — | — |
| Comparator | Gemcitabine | Small molecule | — | — |
| Comparator | Ifosfamide | Small molecule | — | — |
| Comparator | Prednisone | Other / unclassified | — | — |
| Comparator | Vincristine | Small molecule | — | — |